Susceptibility of Cutibacterium acnes to topical minocycline foam.
Acne vulgaris
Cutibacterium acnes
FMX101
Minocycline
Propionibacterium acnes
Tetracycline
Journal
Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
07
11
2019
revised:
13
01
2020
accepted:
27
01
2020
pubmed:
15
2
2020
medline:
8
1
2021
entrez:
15
2
2020
Statut:
ppublish
Résumé
FMX101 4% minocycline foam (FMX101 4%) is a novel, topical minocycline formulation for treatment of acne vulgaris. We report that FMX101 4% had an MIC
Identifiants
pubmed: 32058277
pii: S1075-9964(20)30025-1
doi: 10.1016/j.anaerobe.2020.102169
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Minocycline
FYY3R43WGO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102169Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Joyce Sutcliffe, PhD, and Robert McLaughlin, PhD, served as investigators on the study. Guy Webster, MD, PhD, Andrew Read, PhD, and Karl Drlica, PhD, have served as consultants for Foamix Pharmaceuticals. Inc. USA. Russell Elliott, PhD, and Iain Stuart, PhD, are employees of Foamix Pharmaceuticals, Inc. USA.